The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective-Reference-Cited by-同舟云学术

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

Published:2024-06-28 Issue:7 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Arendrup Maiken Cavling¹²³,Armstrong-James Darius⁴,Borman Andrew M⁵⁶,Denning David W⁷⁸,Fisher Matthew C⁹^ORCID,Gorton Rebecca¹⁰,Maertens Johan¹¹,Martin-Loeches Ignacio¹²¹³¹⁴,Mehra Varun¹⁵^ORCID,Mercier Toine¹⁶¹⁷¹⁸,Price Jessica¹⁹,Rautemaa-Richardson Riina²⁰²¹²²^ORCID,Wake Rachel²³,Andrews Natalie²⁴,White P Lewis¹⁹^ORCID

Affiliation:

1. Unit of Mycology, Statens Serum Institut , Copenhagen , Denmark

2. Department of Clinical Microbiology, Rigshospitalet , Copenhagen , Denmark

3. Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark

4. Department of Infectious Disease, Imperial College London , London , UK

5. Mycology Reference Laboratory, UK Health Security Agency , Bristol , UK

6. Medical Research Council Centre for Medical Mycology, University of Exeter , Exeter , UK

7. Manchester Fungal Infection Group, The University of Manchester , Manchester , UK

8. Global Action For Fungal Infections , Geneva , Switzerland

9. MRC Centre for Global Infectious Disease Analysis, Imperial College London , London , UK

10. Department of Infection Sciences, Health Services Laboratories , London , UK

11. Department of Hematology, University Hospital Gasthuisberg , Leuven , Belgium

12. Department of Intensive Care Medicine, St. James's Hospital , Dublin , Ireland

13. Hospital Clinic, IDIBAPS, Universidad de Barcelona , Spain

14. CIBERes , Barcelona , Spain

15. Department of Haematological Medicine, Kings College Hospital NHS Foundation Trust , London , UK

16. Department of Oncology-Hematology, AZ Sint-Maarten , Mechelen , Belgium

17. Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven , Belgium

18. Department of Hematology, University Hospitals Leuven , Leuven , Belgium

19. Public Health Wales Mycology Reference Laboratory, UHW , Cardiff , UK

20. Department of Infectious Diseases, Manchester University NHS Foundation Trust, Wythenshawe Hospital , Manchester , UK

21. Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, NIHR Manchester Biomedical Research Centre (BRC) at the Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Wythenshawe Hospital , Manchester , UK

22. Mycology Reference Centre Manchester (MRCM), ECMM Excellence Centre of Medical Mycology, Manchester University NHS Foundation Trust, Wythenshawe Hospital , Manchester , UK

23. Institute for Infection and Immunity, St George's University of London , London , UK

24. Napp Pharmaceuticals Limited, a member of the Mundipharma network of independent associated companies, Cambridge, UK

Abstract

Abstract Fungal diseases represent a considerable global health concern, affecting >1 billion people annually. In response to this growing challenge, the World Health Organization introduced the pivotal fungal priority pathogens list (FPPL) in late 2022. The FPPL highlights the challenges in estimating the global burden of fungal diseases and antifungal resistance (AFR), as well as limited surveillance capabilities and lack of routine AFR testing. Furthermore, training programs should incorporate sufficient information on fungal diseases, necessitating global advocacy to educate health care professionals and scientists. Established international guidelines and the FPPL are vital in strengthening local guidance on tackling fungal diseases. Future iterations of the FPPL have the potential to refine the list further, addressing its limitations and advancing our collective ability to combat fungal diseases effectively. Napp Pharmaceuticals Limited (Mundipharma UK) organized a workshop with key experts from Northern Europe to discuss the impact of the FPPL on regional clinical practice.

Funder

Napp Pharmaceuticals Limited

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae372/58437586/ofae372.pdf

Reference144 articles.

1. Global and multi-national prevalence of fungal diseases-estimate precision;Bongomin;J Fungi (Basel),2017

2. Global incidence and mortality of severe fungal disease;Denning;Lancet Infect Dis,2024

3. Tackling emerging fungal threats to animal health, food security and ecosystem resilience;Fisher;Philos Trans R Soc Lond B Biol Sci,2016

4. Continuing shifts in epidemiology and antifungal susceptibility highlight the need for improved disease management of invasive candidiasis;Parslow;Microorganisms,2022

5. Editorial: the World Health Organization (WHO) fungal priority pathogens list in response to emerging fungal pathogens during the COVID-19 pandemic;Parums;Med Sci Monit,2022